These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Safety and efficacy of carbamazepine extended-release capsules in patients with bipolar disorder: QD vs BID.
    Author: Ginsberg LD.
    Journal: Ann Clin Psychiatry; 2006; 18 Suppl 1():27-30. PubMed ID: 16754410.
    Abstract:
    BACKGROUND: Adherence to prescribed pharmacotherapy is an important factor in the success of a selected treatment regimen. Because the dosing frequency of a particular medication can affect adherence rates, this important aspect of treatment must be taken into account. This report presents results from a retrospective assessment of the charts of 23 patients who received once-daily (qd) carbamazepine extended-release capsules (CBZ-ERC) (Shire, Wayne, PA, USA) for the treatment of bipolar disorder. METHODS: The assessment compared qd dosing of CBZ-ERC with twice-daily (bid) dosing by matching the charts of the 23 study subjects to those of 23 similar control patients who had been taking CBZ-ERC dosed bid. RESULTS: In this study, no significant difference was observed in Clinical Global Impression-Improvement (CGI-I) scores between the qd and bid groups. In addition, the percentage of responders (those whose CGI-I score were <or=3) was the same (83%) for both groups. Relapse rates and measures of safety and tolerability were also similar in the two treatment groups. CONCLUSIONS: These findings suggest that CBZ-ERC dosed qd is comparable in efficacy, safety, and tolerability to CBZ-ERC dosed bid for patients with bipolar disorder.
    [Abstract] [Full Text] [Related] [New Search]